Edgewise Therapeutics (EWTX) Short Interest Ratio & Short Volume $15.11 -0.94 (-5.86%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$14.85 -0.26 (-1.72%) As of 10/10/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Edgewise Therapeutics Short Interest DataEdgewise Therapeutics (EWTX) has a short interest of 8.57 million shares, representing 11.49% of the float (the number of shares available for trading by the public). This marks a -15.06% decrease in short interest from the previous month. The short interest ratio (days to cover) is 10.8, indicating that it would take 10.8 days of the average trading volume of 1.03 million shares to cover all short positions.Current Short Interest8,570,000 sharesPrevious Short Interest10,090,000 sharesChange Vs. Previous Month-15.06%Dollar Volume Sold Short$117.41 millionShort Interest Ratio10.8 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares105,350,000 sharesFloat Size74,600,000 sharesShort Percent of Float11.49%Today's Trading Volume771,683 sharesAverage Trading Volume1,030,845 sharesToday's Volume Vs. Average75% Short Selling Edgewise Therapeutics? Sign up to receive the latest short interest report for Edgewise Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEWTX Short Interest Over TimeEWTX Days to Cover Over TimeEWTX Percentage of Float Shorted Over Time Edgewise Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20258,570,000 shares $117.41 million -15.1%11.5%10.8 $13.70 8/31/202510,090,000 shares $144.79 million -1.3%13.5%13.3 $14.35 8/15/202510,220,000 shares $144.61 million +0.3%13.7%13.1 $14.15 7/31/202510,190,000 shares $145.31 million -8.0%13.2%12.1 $14.26 7/15/202511,070,000 shares $148.12 million -12.6%14.4%12.2 $13.38 6/30/202512,660,000 shares $165.97 million +1.0%16.4%10.9 $13.11 6/15/202512,530,000 shares $191.58 million -12.4%16.3%7.9 $15.29 5/31/202514,310,000 shares $203.20 million +12.9%18.6%8.2 $14.20 5/15/202512,680,000 shares $183.23 million -4.4%17.1%7.2 $14.45 4/30/202513,260,000 shares $217.46 million +3.2%17.9%7.5 $16.40 Get the Latest News and Ratings for EWTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/15/202512,850,000 shares $167.31 million +23.7%17.4%7.4 $13.02 3/31/202510,390,000 shares $228.58 million +14.3%14.0%6.1 $22.00 3/15/20259,090,000 shares $233.34 million +4.1%13.5%8.2 $25.67 2/28/20258,730,000 shares $228.46 million +8.3%13.0%8.5 $26.17 2/15/20258,060,000 shares $204.64 million +14.2%12.1%9 $25.39 1/31/20257,060,000 shares $197.82 million +4.8%11.3%8.2 $28.02 1/15/20256,740,000 shares $190.07 million +9.8%10.8%8.2 $28.20 12/31/20246,140,000 shares $163.94 million +8.9%9.8%7.3 $26.70 12/15/20245,640,000 shares $155.78 million -1.7%9.0%6.4 $27.62 11/30/20245,740,000 shares $189.42 million -10.2%9.2%5.2 $33.00 11/15/20246,390,000 shares $200.90 million -12.4%10.2%5.8 $31.44 10/31/20247,290,000 shares $244.73 million -14.1%12.2%6.2 $33.57 10/15/20248,490,000 shares $280.09 million -9.1%14.3%7 $32.99 9/30/20249,340,000 shares $249.28 million +14.3%15.8%8.1 $26.69 9/15/20248,170,000 shares $153.84 million +5.0%14.0%6.8 $18.83 8/31/20247,780,000 shares $145.88 million +21.6%13.3%9 $18.75 8/15/20246,400,000 shares $120.77 million -20.8%11.0%7.6 $18.87 7/31/20248,080,000 shares $137.60 million -5.8%13.6%9.8 $17.03 7/15/20248,580,000 shares $196.22 million +1.2%14.5%11.2 $22.87 6/30/20248,480,000 shares $152.72 million +11.3%14.3%11.5 $18.01 6/15/20247,620,000 shares $133.43 million +17.2%11.6%12.7 $17.51 5/31/20246,500,000 shares $111.35 million -1.4%9.9%9.6 $17.13 5/15/20246,590,000 shares $116.51 million +1.1%10.0%9.2 $17.68 4/30/20246,520,000 shares $116.97 million +13.2%10.4%8.9 $17.94 4/15/20245,760,000 shares $94.92 million +0.7%9.2%7.6 $16.48 3/31/20245,720,000 shares $104.33 million +27.7%9.1%5.7 $18.24 3/15/20244,480,000 shares $75.80 million -18.0%7.1%4.3 $16.92 2/29/20245,460,000 shares $89.16 million +6.4%9.1%5.6 $16.33 2/15/20245,130,000 shares $93.98 million -5.0%8.6%5.4 $18.32 1/31/20245,400,000 shares $96.28 million -33.9%11.5%6.3 $17.83 1/15/20248,170,000 shares $81.70 million -12.5%22.7%10.8 $10.00 12/31/20239,340,000 shares $102.18 million +9.9%25.9%20.1 $10.94 12/15/20238,500,000 shares $61.97 million +20.9%23.7%22.6 $7.29 11/30/20237,030,000 shares $42.74 million +11.1%19.6%24.7 $6.08 11/15/20236,330,000 shares $41.52 million +5.3%17.7%34.2 $6.56 10/31/20236,010,000 shares $38.46 million +4.5%17.0%35.9 $6.40 10/15/20235,750,000 shares $38.58 million +1.6%16.3%36.2 $6.71 9/30/20235,660,000 shares $32.43 million +2.2%16.1%33.2 $5.73 9/15/20235,540,000 shares $35.57 million +1.7%15.7%28.2 $6.42 8/31/20235,450,000 shares $34.06 million +1.1%13.9%26.9 $6.25 8/15/20235,390,000 shares $39.35 million -1.3%13.8%24.5 $7.30 7/31/20235,460,000 shares $39.80 million -12.1%13.7%24.8 $7.29 7/15/20236,210,000 shares $44.84 million +11.7%15.6%27.4 $7.22 6/30/20235,560,000 shares $43.09 million +3.5%14.0%26.4 $7.75 6/15/20235,370,000 shares $46.83 million +12.6%13.5%25 $8.72 5/31/20234,770,000 shares $48.27 million +5.8%12.0%25.3 $10.12 5/15/20234,510,000 shares $40.68 million +1.8%11.3%25.8 $9.02 4/30/20234,430,000 shares $38.85 million +6.2%11.0%25.6 $8.77 4/15/20234,170,000 shares $24.23 million +4.5%10.3%26.5 $5.81 3/31/20233,990,000 shares $26.61 million +6.1%9.9%25.1 $6.67 3/15/20233,760,000 shares $28.76 million -2.1%9.3%25.4 $7.65 2/28/20233,840,000 shares $36.79 million +1.6%9.5%22.4 $9.58 2/15/20233,780,000 shares $37.76 million -2.3%9.3%21.3 $9.99 1/31/20233,870,000 shares $39.59 million +29.9%9.6%21.5 $10.23 1/15/20232,980,000 shares $32.93 million -25.7%7.4%15.8 $11.05 12/30/20224,010,000 shares $35.85 million +38.8%10.0%20 $8.94 12/15/20222,890,000 shares $22.46 million -16.2%7.2%13.3 $7.77 11/30/20223,450,000 shares $30.88 million -3.1%8.6%11.8 $8.95 11/15/20223,560,000 shares $37.38 million -1.1%8.9%12 $10.50 10/31/20223,600,000 shares $34.24 million +8.4%8.9%12.1 $9.51 10/15/20223,320,000 shares $34.59 million +19.0%10.4%10.9 $10.42 9/30/20222,790,000 shares $27.45 million +5.3%10.2%9.2 $9.84 9/15/20222,650,000 shares $24.19 million -12.3%9.7%8.3 $9.13 8/31/20223,020,000 shares $30.44 million -17.0%10.8%12.3 $10.08 8/15/20223,640,000 shares $39.17 million +3.7%13.1%14.7 $10.76 7/31/20223,510,000 shares $33.94 million +3.2%12.5%13.5 $9.67 7/15/20223,400,000 shares $34.54 million +9.0%12.1%13.3 $10.16 6/30/20223,120,000 shares $24.84 million -3.1%11.1%12.6 $7.96 6/15/20223,220,000 shares $19.90 million +1.6%11.5%13.2 $6.18 5/31/20223,170,000 shares $19.81 million -16.1%11.3%14.8 $6.25 5/15/20223,780,000 shares $29.60 million -3.3%13.6%16.7 $7.83 4/30/20223,910,000 shares $31.20 million +1.8%14.0%18.4 $7.98 4/15/20223,840,000 shares $33.48 million -5.9%13.8%16.5 $8.72 3/31/20224,080,000 shares $39.58 million -2.9%14.7%14.7 $9.70 3/15/20224,200,000 shares $42.97 million -10.6%15.1%10.8 $10.23 2/28/20224,700,000 shares $55.41 million +4.7%16.9%10.2 $11.79 2/15/20224,490,000 shares $58.95 million +12.5%18.6%9.8 $13.13 1/31/20223,990,000 shares $54.26 million +8.7%16.5%9.1 $13.60 1/15/20223,670,000 shares $64.23 million +4.6%N/A8.8 $17.50 12/31/20213,510,000 shares $53.63 million +31.0%14.5%9.2 $15.28 12/15/20212,680,000 shares $51.97 million +24.1%11.1%11.8 $19.39 11/30/20212,160,000 shares $37.63 million +45.0%8.9%16.8 $17.42 11/15/20211,490,000 shares $29.25 million +7.2%6.1%15.6 $19.63 10/29/20211,390,000 shares $22.94 million -12.0%5.9%16.7 $16.50 10/15/20211,580,000 shares $28.03 million No Change6.7%23.5 $17.74 9/30/20211,580,000 shares $26.23 million -1.3%6.7%17.2 $16.60 9/15/20211,600,000 shares $25.39 million -23.8%6.9%12.1 $15.87 8/31/20212,100,000 shares $33.26 million +2.4%9.0%12.6 $15.84 8/13/20212,050,000 shares $33.33 million No Change8.8%11 $16.26 EWTX Short Interest - Frequently Asked Questions What is Edgewise Therapeutics' current short interest? Short interest is the volume of Edgewise Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 8,570,000 shares of EWTX short. 11.49% of Edgewise Therapeutics' shares are currently sold short. Learn More on Edgewise Therapeutics' current short interest. What is a good short interest ratio for Edgewise Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EWTX shares currently have a short interest ratio of 11.0. Learn More on Edgewise Therapeutics's short interest ratio. Which institutional investors are shorting Edgewise Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Edgewise Therapeutics: Hudson Bay Capital Management LP, LMR Partners LLP, Hudson Bay Capital Management LP, Group One Trading LLC, Stempoint Capital LP, Affinity Asset Advisors LLC, Walleye Capital LLC, and Walleye Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Edgewise Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.49% of Edgewise Therapeutics' floating shares are currently sold short. Is Edgewise Therapeutics' short interest increasing or decreasing? Edgewise Therapeutics saw a decrease in short interest in September. As of September 15th, there was short interest totaling 8,570,000 shares, a decrease of 15.1% from the previous total of 10,090,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Edgewise Therapeutics' float size? Edgewise Therapeutics currently has issued a total of 105,350,000 shares. Some of Edgewise Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Edgewise Therapeutics currently has a public float of 74,600,000 shares. How does Edgewise Therapeutics' short interest compare to its competitors? 11.49% of Edgewise Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Edgewise Therapeutics: Rhythm Pharmaceuticals, Inc. (7.86%), CRISPR Therapeutics AG (26.18%), Axsome Therapeutics, Inc. (6.91%), Nuvalent, Inc. (11.93%), TG Therapeutics, Inc. (15.50%), Legend Biotech Corporation Sponsored ADR (5.25%), Metsera Inc. (18.47%), Vaxcyte, Inc. (8.75%), Krystal Biotech, Inc. (12.44%), Arrowhead Pharmaceuticals, Inc. (8.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Edgewise Therapeutics stock? Short selling EWTX is an investing strategy that aims to generate trading profit from Edgewise Therapeutics as its price is falling. EWTX shares are trading down $0.94 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Edgewise Therapeutics? A short squeeze for Edgewise Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EWTX, which in turn drives the price of the stock up even further. How often is Edgewise Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EWTX, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies Rhythm Pharmaceuticals Short Squeeze CRISPR Therapeutics Short Squeeze Axsome Therapeutics Short Squeeze Nuvalent Short Squeeze TG Therapeutics Short Squeeze Legend Biotech Short Squeeze Metsera Short Squeeze Vaxcyte Short Squeeze Krystal Biotech Short Squeeze Arrowhead Pharmaceuticals Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EWTX) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
